LAMEA Carrier Screening Market Outlook 2026-2033 | Advanced Technologies and Expanding Clinical Adoption Unlock New Opportunities
Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- "LAMEA Carrier Screening Market Size, Share & Industry Analysis Report by Type, Technology, End-use, Medical Conditions, Country Outlook and Forecast, 2026-2033" has been added to ResearchAndMarkets.com's offering.
The LAMEA carrier screening market is projected to reach USD 158.3 million by 2029, expanding at a compound annual growth rate of 14.7% during 2026-2033. Market growth across Latin America, the Middle East and Africa is being driven by the rising burden of inherited disorders, advances in genomic medicine, healthcare modernization and greater awareness of reproductive genetic testing.
Carrier screening in the LAMEA region has evolved from single-gene testing for selected high-risk populations to comprehensive multi-gene panels. Advances in molecular biology, next-generation sequencing and bioinformatics have increased testing accuracy, expanded regional variant coverage and strengthened the clinical value of reproductive risk assessment.
Healthcare providers are incorporating carrier screening into reproductive planning, prenatal care, premarital programs, fertility services and public health initiatives. Government support, laboratory infrastructure investment, digital health adoption and AI-assisted variant interpretation are also contributing to market expansion. Companies are responding with broader panels, population-specific testing, shorter turnaround times, tele-genetics services, secure data management and cost-efficient testing models.
Type Outlook
By type, the market is segmented into expanded carrier screening and targeted disease screening. Expanded carrier screening dominated the market in 2025 and is expected to maintain its leadership through 2033. The segment is projected to reach USD 104.6 million by 2029, registering a CAGR of 14.3% during the forecast period.
Demand for expanded screening is supported by the growing use of comprehensive panels that evaluate multiple inherited disorders in a single test. Targeted disease screening, forecast to grow at a CAGR of 15.4%, remains important for family-history-based assessments, high-risk populations and region-specific conditions, including sickle cell disease, thalassemia, cystic fibrosis and Tay-Sachs disease.
Technology Outlook
The technology segments include DNA sequencing, polymerase chain reaction, microarrays and other molecular technologies. DNA sequencing led the LAMEA carrier screening market in 2025 and is expected to remain dominant through 2033. The segment is projected to reach USD 74.5 million by 2029, growing at a CAGR of 14.1%.
Next-generation sequencing adoption continues to expand across reference laboratories, diagnostic centers and reproductive healthcare programs. Polymerase chain reaction is expected to record a CAGR of 14.9%, supported by its established use in detecting known mutations. Microarrays remain relevant for high-throughput variant analysis, while other technologies-including digital PCR, isothermal amplification and biosensor-based assays-are projected to grow at a CAGR of 15.5%.
End-Use Outlook
Laboratories dominated the market by end use in 2025 and are expected to retain their leading position through 2033. The laboratory segment is projected to reach USD 70.3 million by 2029, advancing at a CAGR of 14.0%. Growth is supported by centralized genetic testing, sequencing infrastructure, sample-processing capacity and bioinformatics expertise.
Hospitals are forecast to expand at a CAGR of 14.9% as carrier screening becomes more integrated into prenatal care, fertility treatment and specialty genetics services. Physician offices and clinics are expected to post the fastest CAGR of 15.7%, reflecting their role in patient assessment, genetic testing referrals and sample collection. Other end users include fertility centers, genetic counseling centers, academic institutions, mobile testing units and genomic research facilities.
Medical Condition Outlook
The market covers cystic fibrosis, spinal muscular atrophy, sickle cell disease, Tay-Sachs disease, Gaucher disease and other inherited conditions. Cystic fibrosis screening benefits from standardized testing protocols and stronger integration into reproductive healthcare. Spinal muscular atrophy screening is gaining momentum as molecular diagnostic capabilities and prenatal testing access improve.
Sickle cell disease remains a major focus because of its prevalence in several LAMEA populations and the continued expansion of targeted screening programs. Tay-Sachs and Gaucher disease testing remain important within selective and expanded panels. Additional market demand comes from screening for thalassemia, hemophilia, fragile X syndrome, metabolic disorders and rare hereditary diseases.
Country Outlook
Brazil led the LAMEA carrier screening market in 2025 and is expected to remain the largest country market through 2033. The Brazilian market is projected to reach USD 39.0 million by 2029, growing at a CAGR of 13.2%. Expansion is being supported by increased use of comprehensive panels, AI-assisted genetic interpretation, public-private partnerships and the integration of genetic screening into preventive healthcare.
Argentina is forecast to register a CAGR of 16.1%, driven by next-generation sequencing adoption, population-specific screening and public health collaborations. The UAE, projected to grow at a CAGR of 13.7%, is benefiting from premarital screening programs, regulatory support, digital health integration and investment in genetic testing infrastructure.
Saudi Arabia, South Africa and Nigeria are also contributing to regional market growth through premarital testing, sickle cell disease prevention, localized screening panels, tele-genetics and laboratory capacity expansion. Other LAMEA markets are benefiting from decentralized testing models, reproductive health programs and broader access to genomic services.
Key Companies Profiled
LAMEA Carrier Screening Market Segmentation
By Type
By Technology
By End Use
By Medical Condition
By Country
For more information about this report visit https://www.researchandmarkets.com/r/awadsm
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.